Company Summary

Saureus is developing a cost effective point-of-care patient screening technology that can rapidly detect dangerous pathogens that plague hospitals, nursing homes and other healthcare facilities. Initially targeting methicillin resistant Staphylococcus aureus (MRSA), the company will build upon a panel of in-vitro diagnostics, which can be used in a variety of clinical settings where rapid detection can prevent the spread of disease causing organisms and significantly impact the clinical care of patients.

Saureus is a small company with large ambitions and the resources to deliver. We have developed IP to a technology that has the potential to fundamentally alter the market for detecting dangerous pathogens. We have world-class scientific talent, a network of sophisticated technology partners, and we have the energy and enthusiasm to capture this unique opportunity.

Our company is founded on the principles of integrity, loyalty, and hard work. We choose to work with like-minded people who are committed to changing the world for the better. If you share this passion, we encourage you to connect with us.



Management Profiles

Co-founder and Chief Scientific Officer

Ambrose Cheung, M.D. is Professor of Microbiology and Immunology at Dartmouth Medical School. He is an expert in the field of virulence genes in Staphylococcus aureus. In addition to his teaching and research duties, Dr. Cheung is an entrepreneur and a long-distance runner. He holds 5 patents in new and emerging technologies in diagnostics and therapeutics. Dr. Cheung received his B.A from Colby College and his M.D. from Northwestern University.

Co-founder and Chief Executive Officer

George Newcomb is a 20-year veteran of the health care marketplace. In one of his earliest endeavors, Mr. Newcomb successfully launched, developed and sold a managed health care company, as the company's Chief Operating Officer. He has since served as a management consultant to leading companies in the life sciences, industrial manufacturing, and energy industries, and as the commercial leader of the $450 million therapeutic nutrition business at Abbott Laboratories. In addition to his professional interests, George also enjoys running and playing with his two children. He has a B.A. from Connecticut College and an MBA from The Tuck School of Business at Dartmouth College.